Member Info for williamro

Affect

It looks like that name change has jinxed London South East. Much info missing.

EC

Are you also communicating directly with CEOs of companies you think should be using Parsortix? Here you are contacting only those who already share your concerns but have little influence.

The NHS is trying to find the best way to diagnose prostate cancer. Surely they could use Parsortix.

Terrible, incomprehensible, unpronounceable new name.PLEASE RECONSIDER

I hope today’s news that many cancer sufferers in the UK are not getting the best treatment will spur pharma coys and clinicians to look again at Parsortix.

Sorry Hamelin

HAmelin

There is no RNS on this site this morning. Please elucidate.

Presumably FDA approval only applies in the USA, so in theory Parsortix could be used in other countries for other cancers. However those countries may not permit such work if FDA approval has not been granted. There could also be problems with liability if things go wrong.

Has anyone more views or knowledge on this possibility?

Dumped at 9.55.02 with a profit of £350 less costs.

EC

I am a LTH and all your assumptions are wrong.

EC

Instead of wasting so much time here why not get a proper job unless AGL already employs you?

Thanks. So all other cancers will require further FDA approvals. which will take time and cash.

My understanding was that Parsortix was licenced for research but not for monitoring individual patients in a hospital setting. Am I wrong or has something changed? Such a limit undoubtedly would suppress the demand and hence the share price.

If only Angle's shares had tumbled to £10.07 as stated by Berenberg. Current price is 9.475p.

Angle shares ‘attractive’ given growth prospects, says Berenberg

The market has already priced in downward top-line revisions at liquid biopsy company Angle (AGL) and there continues to be potential that makes the share ‘attractive’, says Berenberg.

Analyst Odysseas Manesiotis retained his ‘buy’ recommendation and target price of 120p on the stock, which tumbled 16.5% to £10.07.

There have been several guidance downgrades in the early-stage pharmaceutical development tools sector and Angle was no exception. It revised down top-line expectations for 2023 from £3m to £2.2m after two contracts were ‘pushed out due to cost-control measures as customers aligned with other sector’s cautious spending behaviour’, Manesiotis said.

However, management is predicting a trebling of sales in 2024 which Manesiotis explained ‘falls 29% short of our £9m 2024 sales estimate’.

‘While all this is not great news, we think the shares have largely priced in some downgrades on the back of peers’ reports and, at 5.5x 2024 implied sales for continued significant sales growth, the shares continue to be valued attractively,’ he said.

‘We also think management’s further cost-cutting measures, which allow for a further extended cash runway to mid-2025, are sound, enabling the company to scale back spending until biotech funding recovers.’

More good news but we need big deals to drive the share price.

P45's on their way?

Look at your own presentation EC. Do you mean Too when you say Two? Do you mean Know when you say No?

You need to get out more and consider posting less. When you have real news post on here.

Thank you.